Latest Press Releases
Neurosurgery Navigation & Therapy Grew 59% to $5.4 Million
Positive BioPharma Partner Regulatory Progress and Early Success in Focused Ultrasound Technology Platform Expansion
RMAT Designation Supports an Expedited FDA Development and Review Pathway for Aspen's Investigational Autologous Cell Replacement Therapy for Parkinson's Disease.
Announcement is made after successful proof-of-concept trial in a preclinical model of intravenous delivery of large molecule tracers across the blood-brain barrier guided by prototype systems, including both focused ultrasound hardware and ClearPoint Navigation Software and Robotics
Record Revenue Achieved Including 25% Organic Growth in Devices and 43% Overall Growth
Combined clearance of the navigation and drug delivery technologies enables Canadian neurosurgery centers to leverage the Company's flagship image-guidance workflow and advances ClearPoint Neuro's overall global infrastructure in support of its strategy to enable 20,000 cell and gene therapy procedures annually.
Record Revenue and IRRAS Holdings Acquisition Highlight the Company's 'Fast. Forward.' Strategy
The Company Achieved 20% Comparable Sales Growth in the Fourth Quarter of 2025 at $10.4 Million
Acquisition Will Enhance ClearPoint Neuro's Commercial Scale, Drive Operational Leverage, and Support Its Long-Term Strategy in CNS Drug Delivery Innovation
Site Readiness Continues for Specialized Treatment Centers Envisioned to Support a Growing Number of Cell and Gene Therapy Trial Patients and Later Commercialization
Acquisition Will Further Expand the Potential of ClearPoint Neuro's Drug Delivery Portfolio While Immediately Adding New Indications and Commercial Scale Across a $0.5 Billion Market for the Treatment of Intracranial Bleeding
The clearly established history across global regulatory bodies is expected to de-risk BioPharma partners' pathways towards achieving global scale and standardization.
New Product Category Will Enable Added Flexibility to Support Commercial Launches of Cell and Gene Therapy
Record Revenue and Substantial Cash Infusion Highlight the Company's ‘Fast. Forward.' Strategy
Record Revenue Highlighted by 70% Growth in Single-Use Navigation and Therapy Products
The platform will be showcased at the American Academy of Neurological Surgeons Annual Meeting in Boston on April 25-28, 2025.
Achieved Record Revenue for 2024 and Growth of 31%;
Reduced 2024 Operational Cash Burn by 35%